Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience.
Jose Tinajero, Dat Ngo, Brian Lee, Hoim Kim, Brian Ball, Paul Koller, Idoroenyi Amanam, Hoda Pourhassan, Haris Ali, Salman Otoukesh, Amandeep Salhotra, Amanda Blackmon, Karamjeet Sandhu
Published: 202510.1177/10781552251396885
Abstract
ObjectiveIntensive chemotherapy combinations with venetoclax are being used more frequently for acute myeloid leukemia (AML). In May 2022, a critical shortage of fludarabine prompted cladribine substitution at several institutions in the United State…
Preview only. Read the full abstract at the source